We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Vifor Pharma

News List

CSL to acquire Switzerland’s Vifor Pharma for $11.7bn Pharmaceutical-Technology
December 16, 2021
CSL has signed a definitive agreement for the acquisition of all publicly held stakes of Switzerland-based Vifor Pharma in a deal worth $11.7bn (A$16.4bn) in cash.
FDA Approves Korsuva (difelikefalin) Injection for the Treatment of Moderate-to-Severe Pruritus in Hemodialysis Patients drugs
August 26, 2021
Cara Therapeutics (Nasdaq: CARA) and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved Korsuva (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease.
Vifor Pharma gains commercialisation rights for ChemoCentryx’s Avacopan in Asia pharmaceutical-technology
February 16, 2017
Swiss-based Vifor Pharma, a Galenica Group company, has gained commercialisation rights for ChemoCentryx’s Avacopan (CCX168) for orphan and rare renal diseases in Asia, including Japan and the Middle East.